Wall Street brokerages expect that Fate Therapeutics Inc (NASDAQ:FATE) will post ($0.24) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Fate Therapeutics’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.21). Fate Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would suggest a negative year over year growth rate of 14.3%. The firm is expected to report its next earnings report on Thursday, March 15th.
On average, analysts expect that Fate Therapeutics will report full-year earnings of ($0.97) per share for the current year, with EPS estimates ranging from ($1.00) to ($0.94). For the next financial year, analysts forecast that the business will post earnings of ($0.87) per share, with EPS estimates ranging from ($1.01) to ($0.72). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Fate Therapeutics.
A number of equities analysts have recently weighed in on the company. ValuEngine raised Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Zacks Investment Research lowered Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective (down previously from $10.00) on shares of Fate Therapeutics in a research note on Thursday, January 18th. BMO Capital Markets reissued a “buy” rating and set a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. Finally, BidaskClub raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.71.
Fate Therapeutics (FATE) traded down $0.24 during midday trading on Thursday, hitting $11.26. The stock had a trading volume of 687,800 shares, compared to its average volume of 682,080. The company has a market capitalization of $586.29, a price-to-earnings ratio of -11.98 and a beta of 2.00. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21. Fate Therapeutics has a 1 year low of $2.52 and a 1 year high of $12.45.
ILLEGAL ACTIVITY WARNING: “Fate Therapeutics Inc (FATE) Expected to Post Earnings of -$0.24 Per Share” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3230828/fate-therapeutics-inc-fate-expected-to-post-earnings-of-0-24-per-share.html.
About Fate Therapeutics
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.